An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia

The introduction of imatinib mesylate in 1998 has changed the management of chronic myeloid leukaemia. It is now the first-line therapy for newly diagnosed chronic myeloid leukaemia patients worldwide. However, its long-term survival benefit still needs to be established in clinical setting among As...

Ausführliche Beschreibung